Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Clinical Trial to Evaluate NP-120 (Ifenprodil) as a Therapy for Patients who Experience Respiratory Complications due to COVID-19

Next Previous
Trial Profile

A Phase 2 Clinical Trial to Evaluate NP-120 (Ifenprodil) as a Therapy for Patients who Experience Respiratory Complications due to COVID-19

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 28 Nov 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ifenprodil (Primary) ; Ifenprodil (Primary)
  • Indications Acute lung injury; Adult respiratory distress syndrome; COVID 2019 infections
  • Focus Adverse reactions
  • Sponsors Algernon Pharmaceuticals

Most Recent Events

  • 13 Nov 2020 According to an Algernon Pharmaceuticals media release, the company will be providing an update on its Ifenprodil Phase 2 human clinical studies presented by Christopher J. Moreau, CEO and Dr. Mark Williams, CSO and hosted by Dr. KSS MD PhD. The BioPub webcast will be held on November 13, 2020
  • 14 Apr 2020 New trial record
  • 13 Apr 2020 According to an Algernon Pharmaceuticals media release, based on the feedback, the Company plans to submit, as soon as possible, an Investigational New Drug (IND) application to the FDA, to conduct a Phase 2 clinical trial with Ifenprodil, as a therapy for patients who experience respiratory complications as a result of contracting COVID-19.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top